Wellum G R, Zamenhof R G, Tolpin E I
Int J Radiat Oncol Biol Phys. 1982 Aug;8(8):1339-45. doi: 10.1016/0360-3016(82)90584-3.
The possibility of achieving a therapeutically useful tissue boron distribution for boron neutron capture therapy (BNCT) of cerebral gliomas with boron loaded tumor-specific antibodies is discussed. Using a theoretical tumor-immunological model and RBE dose-depth calculations, the effects of various parameters, e.g. antibody-antigen association constant, antigen site density, number of boron atoms per antibody molecule, etc., on the advantage depth, a relative measure of the resulting radiation dose distributions, are determined. It is shown that with this model a maximum in the advantage depth as a function of the blood boron concentration occurs, the position of which is dependent on the value of the parameters used. Frequently this maximum corresponds to a blood boron-10 concentration range of between 0.1 to 0.5 microgram 10B/g blood. It is concluded that given the pharmacodynamic properties of potentially useful antibody preparations for this type of tumor therapy, advantage depths significantly greater than those obtainable with existing "blood-brain-barrier" compounds are not likely to be easily achieved.
讨论了使用负载硼的肿瘤特异性抗体，实现脑胶质瘤硼中子俘获疗法（BNCT）治疗性有效组织硼分布的可能性。利用理论肿瘤免疫模型和相对生物效应（RBE）剂量深度计算，确定了各种参数，如抗体-抗原结合常数、抗原位点密度、每个抗体分子的硼原子数等，对优势深度（所得辐射剂量分布的相对量度）的影响。结果表明，利用该模型，优势深度随血硼浓度的变化会出现一个最大值，其位置取决于所用参数的值。这个最大值通常对应于血硼-10浓度在0.1至0.5微克10B/克血液之间的范围。得出的结论是，鉴于用于这类肿瘤治疗的潜在有用抗体制剂的药效学特性，不太可能轻易实现比现有“血脑屏障”化合物所能达到的优势深度大得多的优势深度。
